Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) shares traded down 5% during trading on Thursday . The company traded as low as $10.91 and last traded at $11.12, with a volume of 296,112 shares trading hands. The stock had previously closed at $11.71.

A number of research analysts have commented on the stock. Goldman Sachs Group Inc. assumed coverage on shares of Momenta Pharmaceuticals in a research note on Monday, June 6th. They issued a “neutral” rating and a $14.00 price objective on the stock. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, April 27th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. Brean Capital reaffirmed a “buy” rating and issued a $19.00 target price on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $18.00 target price (down previously from $21.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. Six equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $18.40.

The company has a 50 day moving average price of $11.13 and a 200-day moving average price of $10.52. The company’s market cap is $760.77 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings data on Tuesday, May 3rd. The biotechnology company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by $0.03. During the same quarter last year, the business earned ($0.40) EPS. The business had revenue of $19.90 million for the quarter, compared to analysts’ expectations of $28.12 million. Momenta Pharmaceuticals’s revenue was up 132.5% compared to the same quarter last year. On average, analysts forecast that Momenta Pharmaceuticals Inc. will post ($1.33) EPS for the current year.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 5,880 shares of the stock in a transaction on Friday, May 20th. The shares were sold at an average price of $10.18, for a total transaction of $59,858.40. Following the sale, the president now directly owns 349,521 shares of the company’s stock, valued at $3,558,123.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Several hedge funds have modified their holdings of MNTA. Principal Financial Group Inc. boosted its stake in shares of Momenta Pharmaceuticals by 4.6% in the fourth quarter. Principal Financial Group Inc. now owns 423,158 shares of the biotechnology company’s stock worth $6,279,000 after buying an additional 18,504 shares during the period. California Public Employees Retirement System boosted its stake in shares of Momenta Pharmaceuticals by 2.9% in the fourth quarter. California Public Employees Retirement System now owns 200,600 shares of the biotechnology company’s stock worth $2,977,000 after buying an additional 5,600 shares during the period. New York State Common Retirement Fund boosted its stake in shares of Momenta Pharmaceuticals by 2.0% in the fourth quarter. New York State Common Retirement Fund now owns 150,991 shares of the biotechnology company’s stock worth $2,241,000 after buying an additional 2,900 shares during the period. California State Teachers Retirement System boosted its stake in shares of Momenta Pharmaceuticals by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 113,170 shares of the biotechnology company’s stock worth $1,679,000 after buying an additional 1,801 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Momenta Pharmaceuticals by 2.6% in the fourth quarter. Swiss National Bank now owns 91,500 shares of the biotechnology company’s stock worth $1,358,000 after buying an additional 2,300 shares during the period.

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.